Cargando…
Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
OBJECTIVE: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805043/ https://www.ncbi.nlm.nih.gov/pubmed/26758973 http://dx.doi.org/10.4274/jcrpe.2219 |
_version_ | 1782423080314863616 |
---|---|
author | Aydoğan, Berna İmge Yüksel, Bağdagül Tuna, Mazhar Müslüm Navdar Başaran, Mehtap Akkurt Kocaeli, Ayşen Ertörer, Melek Eda Aydın, Kadriye Güldiken, Sibel Şimşek, Yasin Cihan Karaca, Züleyha Yılmaz, Merve Aktürk, Müjde Anaforoğlu, İnan Kebapçı, Nur Duran, Cevdet Taşlıpınar, Abdullah Kulaksızoğlu, Mustafa Gürsoy, Alptekin Dağdelen, Selçuk Erdoğan, Murat Faik |
author_facet | Aydoğan, Berna İmge Yüksel, Bağdagül Tuna, Mazhar Müslüm Navdar Başaran, Mehtap Akkurt Kocaeli, Ayşen Ertörer, Melek Eda Aydın, Kadriye Güldiken, Sibel Şimşek, Yasin Cihan Karaca, Züleyha Yılmaz, Merve Aktürk, Müjde Anaforoğlu, İnan Kebapçı, Nur Duran, Cevdet Taşlıpınar, Abdullah Kulaksızoğlu, Mustafa Gürsoy, Alptekin Dağdelen, Selçuk Erdoğan, Murat Faik |
author_sort | Aydoğan, Berna İmge |
collection | PubMed |
description | OBJECTIVE: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic thyroidectomy (PTx) in mutation carriers were also assessed. METHODS: Genetic testing for MTC and pheochromocytoma was conducted between July 2008 and January 2012 in 512 patients. Application forms and RET mutation analyses of these patients whose blood samples were sent from various centers around Turkey were assessed retrospectively. An evaluation form was sent to the physicians of the eligible 319 patients who had confirmed sporadic MTC, familial MTC (FMTC), multiple endocrine neoplasia type 2 (MEN2), or who were mutation carriers. Physicians were asked to give information about the surgical history, latest calcitonin levels, morbidity, mortality, genetic screening, and PTx among family members. Twenty-five centers responded by filling in the forms of 192 patients. RESULTS: Among the 319 patients, RET mutation was detected in 71 (22.3%). Cys634Arg mutation was the most prevalent mutation (43.7%), followed by Val804Met in 18 patients (25.4%), and Cys634Tyr in 6 patients (8.5%). Among 192 MTC patients, the diagnosis was sporadic MTC in 146 (76.4%), FMTC in 14 (7.3%), MEN2A in 15 patients (7.9%), and MEN2B in one patient. The number of mutation carriers among 154 apparently sporadic MTC patients was 8 (5.2%). Ten patients were submitted to PTx out of twenty-four mutation carriers at a mean age of 35±19 years. CONCLUSION: Turkish people have a similar RET proto-oncogene mutation distribution when compared to other Mediterranean countries. Despite free RET gene testing, the number of the PTx in Turkey is limited and relatively late in the life span of the carriers. This is mainly due to patient and family incompliance and incomplete family counselling. |
format | Online Article Text |
id | pubmed-4805043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-48050432016-04-06 Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey Aydoğan, Berna İmge Yüksel, Bağdagül Tuna, Mazhar Müslüm Navdar Başaran, Mehtap Akkurt Kocaeli, Ayşen Ertörer, Melek Eda Aydın, Kadriye Güldiken, Sibel Şimşek, Yasin Cihan Karaca, Züleyha Yılmaz, Merve Aktürk, Müjde Anaforoğlu, İnan Kebapçı, Nur Duran, Cevdet Taşlıpınar, Abdullah Kulaksızoğlu, Mustafa Gürsoy, Alptekin Dağdelen, Selçuk Erdoğan, Murat Faik J Clin Res Pediatr Endocrinol Original Article OBJECTIVE: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic thyroidectomy (PTx) in mutation carriers were also assessed. METHODS: Genetic testing for MTC and pheochromocytoma was conducted between July 2008 and January 2012 in 512 patients. Application forms and RET mutation analyses of these patients whose blood samples were sent from various centers around Turkey were assessed retrospectively. An evaluation form was sent to the physicians of the eligible 319 patients who had confirmed sporadic MTC, familial MTC (FMTC), multiple endocrine neoplasia type 2 (MEN2), or who were mutation carriers. Physicians were asked to give information about the surgical history, latest calcitonin levels, morbidity, mortality, genetic screening, and PTx among family members. Twenty-five centers responded by filling in the forms of 192 patients. RESULTS: Among the 319 patients, RET mutation was detected in 71 (22.3%). Cys634Arg mutation was the most prevalent mutation (43.7%), followed by Val804Met in 18 patients (25.4%), and Cys634Tyr in 6 patients (8.5%). Among 192 MTC patients, the diagnosis was sporadic MTC in 146 (76.4%), FMTC in 14 (7.3%), MEN2A in 15 patients (7.9%), and MEN2B in one patient. The number of mutation carriers among 154 apparently sporadic MTC patients was 8 (5.2%). Ten patients were submitted to PTx out of twenty-four mutation carriers at a mean age of 35±19 years. CONCLUSION: Turkish people have a similar RET proto-oncogene mutation distribution when compared to other Mediterranean countries. Despite free RET gene testing, the number of the PTx in Turkey is limited and relatively late in the life span of the carriers. This is mainly due to patient and family incompliance and incomplete family counselling. Galenos Publishing 2016-03 2016-03-01 /pmc/articles/PMC4805043/ /pubmed/26758973 http://dx.doi.org/10.4274/jcrpe.2219 Text en © Journal of Clinical Research in Pediatric Endocrinology, Published by Galenos Publishing. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Aydoğan, Berna İmge Yüksel, Bağdagül Tuna, Mazhar Müslüm Navdar Başaran, Mehtap Akkurt Kocaeli, Ayşen Ertörer, Melek Eda Aydın, Kadriye Güldiken, Sibel Şimşek, Yasin Cihan Karaca, Züleyha Yılmaz, Merve Aktürk, Müjde Anaforoğlu, İnan Kebapçı, Nur Duran, Cevdet Taşlıpınar, Abdullah Kulaksızoğlu, Mustafa Gürsoy, Alptekin Dağdelen, Selçuk Erdoğan, Murat Faik Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey |
title | Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey |
title_full | Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey |
title_fullStr | Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey |
title_full_unstemmed | Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey |
title_short | Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey |
title_sort | distribution of ret mutations and evaluation of treatment approaches in hereditary medullary thyroid carcinoma in turkey |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805043/ https://www.ncbi.nlm.nih.gov/pubmed/26758973 http://dx.doi.org/10.4274/jcrpe.2219 |
work_keys_str_mv | AT aydoganbernaimge distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT yukselbagdagul distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT tunamazharmuslum distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT navdarbasaranmehtap distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT akkurtkocaeliaysen distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT ertorermelekeda distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT aydınkadriye distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT guldikensibel distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT simsekyasin distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT cihankaracazuleyha distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT yılmazmerve distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT akturkmujde distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT anaforogluinan distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT kebapcınur distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT durancevdet distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT taslıpınarabdullah distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT kulaksızoglumustafa distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT gursoyalptekin distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT dagdelenselcuk distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey AT erdoganmuratfaik distributionofretmutationsandevaluationoftreatmentapproachesinhereditarymedullarythyroidcarcinomainturkey |